RxDoctor Payments Data

Leonardo Amper, MD

Internal Medicine · Johnstown, PANPI 1346225869

Payments from drug & device makers

$8,822in general payments, 2019–2025

Across 562 payments — averaging $15.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • AbbVie$845
  • E.r. Squibb & Sons, L.L.C.$785
  • Novo Nordisk$704
  • GSK$608
  • AstraZeneca$531
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$8,798100%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,822 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$56,160
Medicare patients
113
Services billed
614

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban217$168,817
Trelegy ElliptaFluticasone/Umeclidin/Vilanter115$105,575
FarxigaDapagliflozin Propanediol97$96,256
JardianceEmpagliflozin80$84,983
OzempicSemaglutide56$72,614
MyrbetriqMirabegron73$47,354
XareltoRivaroxaban53$46,928
TrulicityDulaglutide40$45,115
EntrestoSacubitril/Valsartan26$38,206
TradjentaLinagliptin38$34,105
ProliaDenosumab17$27,366
RybelsusSemaglutide24$27,087
JanuviaSitagliptin Phosphate17$25,284
MounjaroTirzepatide24$24,475
LinzessLinaclotide17$21,058

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,045$168,817217 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$608$124,580147 claims
Boehringer IngelheimJardiance, Tradjenta$194$119,088118 claims
Novo NordiskOzempic, Rybelsus$704$99,70280 claims
AstraZenecaFarxiga$531$96,25697 claims
Lilly USA, LLCTrulicity, Mounjaro$347$69,58964 claims
Astellas Pharma US IncMyrbetriq$113$47,35473 claims
Johnson & JohnsonXarelto$315$46,92853 claims
NovartisEntresto$49$38,20626 claims
AmgenProlia$349$27,36617 claims
MerckJanuvia$342$25,28417 claims
AbbVieLinzess, Synthroid$845$24,31682 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Johnstown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →